/ /

  • linkedin
  • Increase Font
  • Sharebar

    Drug-delivery platforms offer more options and promise for clinicians


    Ohr Pharmaceutical

    Ohr is developing a platform to produce micro and macro particles of any shape or size that can be loaded with drugs. Work to date shows that the platform can be used with a variety of agents, small molecules, large molecules, biologics, and layers of different agents for multi-drug dosing.

    “These particles can be used to treat any indication in the eye,” said Barbara Wirostko, MD, vice president of clinical development. “These particles can be placed as needed in, on, or around any portion of the eye for glaucoma, steroid-induced glaucoma, allergies, retinal disease, and more.”         

    One version of the platform is being developed for a variety of VEGF-induced retinopathies. A wet AMD product is moving into phase III trials while products for retinal vein occlusion, proliferative diabetic retinopathy, and diabetic macular edema are in phase II trials. Particles designed to treat steroid-induced glaucoma have demonstrated zero order release profiles for as long as 6 months. The same technology is also feasible for large molecule biologic agents.       

    “We see a large unmet need for steroid-induced glaucoma,” Dr. Wirostko said. “Due to the increasing delivery of steroids to the eye, there is an emerging need to treat this type of glaucoma. Disease is directly related to the potency of the steroid, the delivery mode of the steroid, as well as the frequency of the steroid. And we don’t have a good solution.”      

    About 30% of the general population appears to be susceptible to steroid-induced glaucoma, she continued, although patients with primary open-angle glaucoma (POAG) have a higher likelihood of developing the disease.

    “With an emerging and increasing burden of diabetes and higher use of intravitreal steroids, there is going to be a higher incidence and prevalence of steroid-induced glaucoma,” Dr. Wirostko said. “We are positioned to move this technology forward with a glaucoma-sustained delivery product.”

    Selkie Therapeutics

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results